华佗品牌怎么样 申请店铺

我要投票 华佗在中草药行业中的票数:333 更新时间:2025-02-05
华佗是哪个国家的品牌?「华佗」是 华佗国药股份有限公司 旗下著名品牌。该品牌发源于安徽,由创始人李宏良在2009期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
华佗怎么样

安徽华佗国药股份有限公司位于三朝古都,华佗故里,中国历史文化名城,全国四大药都之首—安徽省亳州市。安徽华佗国药股份有限公司已有50多年建厂历史,设计规模及生产能力居安徽前列,在全国也位列前茅;2001年又斥资上亿元,由省医药设计院,参照中外合资先进企业的优点和特色,经科学规划、精心设计、高标准建设、全面实施国家医药GMP工程,并于2002年12月8日一次性通过国家GMP认证,是国内第一批通过GMP认证的企业之一。

致力于发展传统的中医药文化,倡导安全用药,安心用药,秉承“用良心制好药”的理念,华佗国药厂自始就以质量控制为第一要务,厂内配有全进口日本岛津公司高效液相仪、气相色谱仪、薄层扫描仪、紫光分析仪等检测设备,堪称高起点,高标准的现代化中成药制造企业和中药材加工基地。厂内现有国内领先的全自动生产灌装线、自动颗粒包装机、自动胶囊填充机、自动铝塑包装机、全自动高效包衣机等现代化设备均完全符合国家GMP标准。并配有空压冷冻系统、净化系统、电视监控系统、数字化管理等一系列先进管理系统;为了进一步的提高中药现代化的进程,我们成立了安徽华佗现代中药研发中心,致力于中国中药现代化的研究与开发。

安徽华佗国药股份有限公司,目前具有年加工中药材5600吨的生产能力,产品有片剂、丸剂、胶囊剂、颗粒剂、单味药颗粒、中药饮片六大剂类型,60多个品种,年产值可达5.6亿元,产品大部分出口,畅销亚、欧、美三十多个国家和地区。在不久的将来,安徽华佗国药股份有限公司将成为中国最大的中成药生产企业和中药材加工基地。

在华佗国药厂的发展历史上,曾受到诸多中央和省市领导人的关心,国务院总理温家宝、副总理回良玉及安徽省历届主要党政领导人曾亲自前往华佗国药厂视察。

安徽华佗国药股份有限公司始终坚持“质量第一,诚信为本,用良心制好药”的经营理念,确保人民安全用药,保障人民身体健康,促进医药经济发展。竭诚欢迎海内外客商来厂洽谈业务,进行经贸合作。

Anhui Huatuo State Pharmaceutical Co., Ltd. is located in Bozhou City, Anhui Province, the capital of three dynasties, the hometown of Huatuo, the famous historical and cultural city of China and the first of the four major pharmaceutical capitals in China. Anhui Huatuo State Pharmaceutical Co., Ltd. has a history of more than 50 years. Its design scale and production capacity rank the top in Anhui Province, and it ranks the top in the country. In 2001, it also spent more than 100 million yuan. With reference to the advantages and characteristics of advanced Sino foreign joint ventures, the Provincial Pharmaceutical Design Institute carried out the national pharmaceutical GMP project through scientific planning, careful design, high standard construction and comprehensive implementation One time through the national GMP certification, is the first batch of domestic enterprises through GMP certification. Committed to the development of traditional Chinese medicine culture, advocating safe drug use, reassuring drug use, and adhering to the concept of "making good medicine with conscience", huatuoguo pharmaceutical factory has been focusing on quality control since the beginning. The factory is equipped with imported high-performance liquid chromatography, gas chromatograph, thin-layer scanner, violet light analyzer and other testing equipment of Shimadzu company of Japan, which can be regarded as a high starting point and a high standard of modernization Pharmaceutical manufacturing enterprises and traditional Chinese medicine processing bases. In the factory, the domestic leading full-automatic production filling line, automatic particle packaging machine, automatic capsule filling machine, automatic aluminum plastic packaging machine, automatic high-efficiency coating machine and other modern equipment are all in full compliance with the national GMP standards. In order to further improve the modernization process of traditional Chinese medicine, we have established Anhui Huatuo modern Chinese medicine research and development center, which is dedicated to the research and development of the modernization of traditional Chinese medicine. Anhui Huatuo State Pharmaceutical Co., Ltd. has an annual production capacity of processing 5600 tons of Chinese herbal medicines. Its products include six types of tablets, pills, capsules, granules, single drug granules and Chinese herbal pieces, with more than 60 varieties. Its annual output value can reach 560 million yuan. Most of its products are exported and sold well in more than 30 countries and regions in Asia, Europe and the United States. In the near future, Anhui Huatuo Guoyao Co., Ltd. will become the largest Chinese patent medicine manufacturer and Chinese herbal medicine processing base in China. In the development history of Huatuo state pharmaceutical factory, it has been concerned by many central and provincial leaders. Premier Wen Jiabao of the State Council, Vice Premier Hui Liangyu and major party and government leaders of Anhui Province have personally visited Huatuo state pharmaceutical factory. Anhui Huatuo State Pharmaceutical Co., Ltd. always adheres to the business philosophy of "quality first, integrity-based, making good medicine with conscience", so as to ensure people's safe drug use, ensure people's health and promote the development of medical economy. We sincerely welcome customers from home and abroad to come to our factory to discuss business and carry out economic and trade cooperation.

本文链接: https://brand.waitui.com/e16df2ef3.html 联系电话:0551-4669444

千城特选小程序码

7×24h 快讯

美股大型科技股盘前多数下跌,谷歌跌超7%

36氪获悉,美股大型科技股盘前多数下跌,截至发稿,谷歌跌超7%,亚马逊、苹果跌超1%,特斯拉跌0.92%,微软跌0.36%,Meta跌0.35%,奈飞跌0.14%;英伟达涨近1%。

47分钟前

热门中概股美股盘前多数走弱,拼多多跌超7%

36氪获悉,热门中概股美股盘前多数走弱,截至发稿,拼多多跌超7%,理想汽车、微博跌超3%,阿里巴巴、京东、百度、蔚来跌超2%,小鹏汽车、爱奇艺跌超1%;B站涨超1%。

47分钟前

君实生物:AWT020注射用无菌粉末临床试验申请获批

36氪获悉,君实生物公告,近日,公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,AWT020注射用无菌粉末(项目代号“JS213”)的临床试验申请获得批准。JS213是PD-1和白细胞介素-2双功能性抗体融合蛋白,主要用于晚期恶性肿瘤的治疗。

47分钟前

渣打集团任命Maria Ramos接替韦浩思担任集团主席

2月4日,渣打集团董事会宣布,鉴于韦浩思(José Viñals)已接近他服务满9年的任期,已任命Maria Ramos(65岁)接替韦浩思担任集团主席。待取得监管批准后,Maria将于公司在2025年5月8日举行的2025年股东周年大会后履新,而韦浩思届时将自董事会退任。(界面)

47分钟前

三六零:公司暂未向DeepSeek提供任何服务

36氪获悉,三六零公告,公司股票于2025年1月24日、1月27日、2月5日连续三个交易日内收盘价格涨幅偏离值累计超过20%,属于股票交易异常波动情形。经自查,公司注意到相关平台将公司股票纳入DeepSeek概念股。公司就相关事项澄清说明如下:在DeepSeek基于MIT开源协议的生态环境下,公司旗下的部分产品进行了DeepSeek的接入与本地化部署;公司暂未向DeepSeek提供任何服务。除上述事项外,公司未发现其他可能对公司股票交易价格产生较大影响的、需要公司澄清或回应的媒体报道或市场传闻

47分钟前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询